One in nine men will be diagnosed with prostate cancer, including more than 174,000 throughout the U.S. this year alone.
This November, we're putting down the razor and picking up the cause by participating in the Grow & Give campaign with ZERO - The End of Prostate Cancer.
Join our team! Your participation will help raise awareness and your donation will help fund research, patient programs that go directly to helping men and their families, free testing, and educational programs.
Support our team today! You'll feel proud knowing that you're helping keep families together and saving lives.
About our company:
Genomic Health is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.
The Oncotype DX Genomic Prostate Score (GPS) assay is the only genomic assay designed for men with clinically low-risk cancer to help make treatment decisions at the time of diagnosis. The assay analyzes prostate cancer gene activity to predict disease aggressiveness.